Financial Performance - Citius Pharmaceuticals reported $3.9 million in revenue for the fiscal first quarter 2026, generated from initial sales of LYMPHIR in December 2025[1][2]. - The net loss applicable to common stockholders was $8.2 million, or $(0.38) per share, compared to a net loss of $9.8 million, or $(1.30) per share, in the prior-year period[8][15]. - Net loss for 2025 was $9,393,889, an improvement from a net loss of $10,281,246 in 2024[17]. - Stock-based compensation expense increased to $4,280,227 in 2025 from $2,524,824 in 2024[17]. - Net cash used in operating activities rose to $13,008,822 in 2025 compared to $4,725,852 in 2024[17]. Cash and Financing - Cash and cash equivalents totaled $7.7 million as of December 31, 2025, with net proceeds of approximately $20.9 million from equity financings during the quarter[8]. - Net proceeds from common stock offerings significantly increased to $20,877,925 in 2025 from $2,574,051 in 2024[17]. - Cash and cash equivalents at the end of the period reached $7,721,393 in 2025, up from $1,100,079 in 2024[17]. Research and Development - Research and development expenses decreased to $1.6 million from $2.1 million in the prior-year period, reflecting reduced clinical development activity[8]. - Citius Pharma is advancing its late-stage pipeline, which includes Mino-Lok and Halo-Lido, with ongoing engagement with the FDA[4][8]. Market Strategy and Opportunities - The company aims to expand patient access and market penetration through a technology-driven platform and anticipates growth from international market opportunities[3]. - Citius Oncology's LYMPHIR is targeted for adult patients with relapsed or refractory Stage I–III cutaneous T-cell lymphoma, with an estimated initial market exceeding $400 million[5][9]. - The company has initiated agreements for international patient access to LYMPHIR through Named Patient Programs in Europe and the Middle East[8]. - Citius Oncology has deployed an AI-enabled commercial platform to enhance physician engagement and market penetration in a concentrated prescriber base[8]. Operational Changes - General and administrative expenses increased to $5.7 million compared to $5.4 million in the prior-year period[8]. - License fee payments in investing activities amounted to $4,400,000 in 2025, with no such payments in 2024[17]. - Changes in accounts receivable resulted in a decrease of $4,049,111 in 2025, with no allowances reported in 2024[17]. - Inventory decreased by $352,649 in 2025, a significant improvement compared to a decrease of $6,112,603 in 2024[17]. - Accrued expenses decreased by $5,722,097 in 2025, contrasting with an increase of $6,225,151 in 2024[17]. - Interest paid in 2025 was $14,460, with no interest paid reported in 2024[17].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number 001-38174 Citius Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) | Ne ...

stockholders$(8,220,785)$(9,768,246)Net Loss Per Share - Basic and Diluted$(0.38)$(1.30)Weighted Average Common Shares OutstandingBasic and diluted (include pre-funded warrants from the October 2025 offering)21,495,2747,492,460CITIUS PHARMACEUTICALS, INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWSFOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND 2024(Unaudited)20252024Cash Flows From Operating Activities:Net loss$(9,393,889)$(10,281,246)Adjustments to reconcile net loss to net cash used in operating acti ...

Financing Activities15,125,489-Net Change in Cash and Cash Equivalents3,370,543-Cash and Cash Equivalents – Beginning of Period3,924,908112Cash and Cash Equivalents – End of Period$7,295,451$112Supplemental Disclosures of Cash Flow Information and Non-cash Transactions:Interest Paid$14,460$-SOURCE Citius Oncology, Inc.## 21%[more press release views with Request a Demo]## Also from this source### Citius Oncology Expands International Distribution of LYMPHIRâ"¢ to European Union Through Exclusive Agreement w ...

Core Insights - Citius Oncology has entered into an exclusive distribution agreement with Uniphar to expand access to LYMPHIR in Europe, marking its third international distribution partnership [1][2] - The agreement allows Uniphar to manage access and distribution of LYMPHIR in specific territories in Western and Eastern Europe through country-specific managed access programs [1] - LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) and is not yet approved for commercial use outside the United States [1][2] Company Overview - Citius Oncology, a subsidiary of Citius Pharmaceuticals, focuses on developing and commercializing novel targeted oncology therapies [2] - The initial market for LYMPHIR is estimated to exceed $400 million and is considered underserved by existing therapies [2] - Citius Oncology has robust intellectual property protections, including orphan drug designation and pending patents for immuno-oncology use [2] Product Information - LYMPHIR (denileukin diftitox-cxdl) is indicated for use in Stage I-III CTCL after at least one prior systemic therapy [1] - The drug works by binding to IL-2 receptors on cancer cells, leading to cell death through inhibition of protein synthesis [1] - In 2021, denileukin diftitox received regulatory approval in Japan for treating relapsed or refractory CTCL and peripheral T-cell lymphoma [1] Distribution Partner - Uniphar is an international healthcare services company that supports over 200 pharmaceutical and medical technology manufacturers [2] - The partnership with Citius Oncology aims to improve patient outcomes for those with relapsed or refractory CTCL [1][2] - Uniphar operates across 180 countries and integrates various services to support the full product lifecycle from research to commercialization [2]

Market Performance - U.S. stocks experienced an upward trend, with the Dow Jones index increasing by over 200 points, closing up 0.48% at 48,673.55. The NASDAQ rose 0.09% to 23,582.81, and the S&P 500 gained 0.25% to 6,927.29 [1] - Consumer staples shares rose by 0.7%, while communication services stocks fell by 0.1% [1] Economic Indicators - U.S. initial jobless claims decreased by 10,000 to 214,000 for the week ending December 20, which was better than market estimates of 223,000 [2][10] Commodity Market - In commodity trading, oil prices fell by 0.2% to $58.28, gold decreased by 0.3% to $4,493.50, and silver dropped by 0.2% to $71.00. Conversely, copper rose by 0.2% to $5.5640 [5] European Market - European shares showed mixed results, with the eurozone's STOXX 600 gaining 0.1%, while Spain's IBEX 35 Index fell by 0.06%. London's FTSE 100 decreased by 0.19%, Germany's DAX 40 rose by 0.23%, and France's CAC 40 slipped by 0.01% [6] Asian Market - Asian markets closed mixed, with Japan's Nikkei 225 down 0.14%, Hong Kong's Hang Seng up 0.17%, China's Shanghai Composite up 0.53%, and India's BSE Sensex down 0.14% [7] Company Updates - Edgewise Therapeutics Inc (NASDAQ:EWTX) shares surged 21% to $26.36 following updates from the ongoing CIRRUS-HCM Phase 2 trial of EDG-7500 [9] - Multi Ways Holdings Ltd (NYSE:MWG) shares increased by 62% to $0.41 after reporting a year-over-year increase in H1 EPS results [9] - Omeros Corp (NASDAQ:OMER) shares rose 68% to $14.72 after the FDA approved YARTEMLEA for treating hematopoietic stem cell transplant–associated thrombotic microangiopathy [9] - Hycroft Mining Holding Corporation (NASDAQ:HYMC) shares fell 10% to $24.56 after a significant rally, influenced by commodity market conditions and a major divestiture by AMC Entertainment Holdings Inc (NYSE:AMC) [9] - Citius Pharmaceuticals Inc (NASDAQ:CTXR) shares dropped 24% to $0.80 despite reporting better-than-expected earnings for the fourth quarter [9] - SMX (Security Matters) PLC (NASDAQ:SMX) shares decreased by 9% to $135.00 [9]

Group 1 - UiPath Inc. will join the S&P Midcap 400, replacing Synovus Financial Corp., effective January 2, 2026, leading to a 6.8% increase in shares to $17.05 in after-hours trading [1] - Agios Pharmaceuticals Inc. received FDA approval for AQVESME™ for treating anemia in adults with alpha- or beta-thalassemia, but shares fell 1.4% to $24.59 [1] - Can Fite Biopharma announced a 1-for-3,000 reverse share split, resulting in a 28.8% drop in shares to $0.17 in after-hours trading [1] - Citius Pharmaceuticals reported a quarterly loss of 11 cents per share, better than the expected loss of 43 cents, causing shares to surge 22.1% to $1.27 [1] - Ramaco Resources announced a $100 million stock repurchase plan, leading to a 7.1% increase in shares to $18.09 in after-hours trading [1]

Financial Performance - Citius Pharmaceuticals reported a net loss of $39.7 million, or $3.38 per share, for the fiscal year ended September 30, 2025, compared to a net loss of $40.2 million, or $5.97 per share, for the previous year[6]. - Net loss for 2025 was $(39,740,269), slightly higher than $(39,425,839) in 2024[15]. - Stock-based compensation decreased to $10,836,291 from $11,839,678 year-over-year[15]. - Net cash used in operating activities improved to $(26,552,738) from $(28,201,375) in the previous year[15]. - Net cash used in investing activities increased to $(5,750,000) from $(5,000,000) in 2024[15]. - Net proceeds from common stock offerings rose significantly to $32,303,148 compared to $13,803,684 in 2024[15]. - Cash and cash equivalents stood at $4.3 million as of September 30, 2025, compared to $3.3 million in the previous year[6]. - Cash and cash equivalents at the end of 2025 were $4,252,290, up from $3,251,880 in 2024[15]. - Inventory changes resulted in a significant increase in cash outflow of $(12,649,207) compared to $(2,133,871) in 2024[15]. - Accounts payable increased to $8,766,481 from $1,999,877 year-over-year, indicating improved supplier financing[15]. - Operating lease right-of-use asset and liability recorded was $786,697, reflecting new lease agreements[15]. - Interest paid in 2025 was $187,389, indicating ongoing financing costs[15]. Research and Development - Research and development expenses decreased to $9.2 million for the fiscal year 2025, down from $11.9 million in 2024, while general and administrative expenses slightly increased to $18.5 million from $18.2 million[6]. - Citius is actively engaging with the FDA to advance Mino-Lok and explore additional indications and markets for LYMPHIR[2]. Product Launch and Market Access - Citius Oncology launched LYMPHIR™, a novel immunotherapy for cutaneous T-cell lymphoma, in December 2025, with an estimated initial market exceeding $400 million[3][5]. - Citius secured access to LYMPHIR in 19 international markets through regional distribution partners, allowing access under named patient programs[3]. - The company executed service agreements with three leading U.S. pharmaceutical wholesalers to distribute LYMPHIR throughout the U.S.[3]. - Citius ensured production and sufficient supply of LYMPHIR for up to 18 months of estimated commercial demand[3]. Assets and Financial Position - The total assets of Citius Pharmaceuticals increased to $130.9 million as of September 30, 2025, compared to $116.7 million in 2024[11].

Group 1 - The article does not provide any relevant content regarding the company or industry [1]

Core Insights - Citius Oncology has launched LYMPHIR, a novel immunotherapy for treating relapsed or refractory Stage I–III cutaneous T-cell lymphoma (CTCL) in the U.S. as of December 2025, marking a significant transition from a pre-revenue to a revenue-generating company [1][2][6] Business Highlights - The company has executed service agreements with three leading U.S. pharmaceutical wholesalers to distribute LYMPHIR to various healthcare organizations [6] - Citius Oncology has secured access to LYMPHIR in 19 international markets through regional distribution partners via Named Patient Programs, initiating its global access strategy [6] - A collaboration with Verix has been announced to utilize its Tovana AI-powered platform for enhancing commercial targeting and provider engagement [6] - Preliminary results from a Phase I clinical trial combining pembrolizumab and LYMPHIR in cancer patients have shown promise [6] Financial Highlights - Citius Oncology completed $36 million in strategic financings, including an $18 million private placement and registered direct offering on December 10, 2025 [1][4] - As of September 30, 2025, the company reported cash and cash equivalents of $3.9 million, with a net loss of $24.8 million, or ($0.34) per share, compared to a net loss of $21.1 million, or ($0.31) per share for the previous fiscal year [4][12] - Research and development expenses increased to $6.4 million for the fiscal year ended September 30, 2025, up from $4.9 million in the prior year [4][12] Market Potential - The initial market for LYMPHIR is estimated to exceed $400 million and is considered underserved by existing therapies, indicating significant growth potential [7] - The company holds robust intellectual property protections, including orphan drug designation and pending patents, which support its competitive positioning in the oncology market [7]